Aminoglycosides
High-yield Verified · Oct 2026Prototype: gentamicin
Aminoglycosides are a class of medications used for serious Gram-negative infections.
Gentamicin and relatives — bactericidal protein-synthesis inhibitors with a narrow safety margin. Watch for -micin.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Attacking the bacterial ribosome
Where penicillins and cephalosporins wreck the bacterial cell wall, aminoglycosides attack the bacterium’s protein factory — the ribosome. They bind the 30S ribosomal subunit and cause it to misread the genetic code, producing garbled, non-functional proteins. Because the damage is lethal, aminoglycosides are bactericidal (they kill), reserved mainly for serious Gram-negative infections and often combined with a cell-wall agent for synergy.
Their killing is concentration-dependent: a high peak relative to the bug’s susceptibility kills best, and they keep working after the level falls (a "post-antibiotic effect"). This is why modern dosing often uses a large once-daily dose — maximize the peak, then let the level trough low to protect the kidney.
02 The two toxicities that define the class
The same drug that saves the patient can injure two organs. Nephrotoxicity: aminoglycosides accumulate in the kidney’s proximal tubule cells and can cause acute kidney injury — usually reversible if caught early. Ototoxicity: they accumulate in the inner ear and damage the cochlea (hearing loss) and vestibular apparatus (dizziness, balance loss) — and this damage is often permanent.
Both toxicities rise when the drug lingers — high trough levels, prolonged courses, dehydration, existing kidney disease, and other nephro-/oto-toxic drugs (loop diuretics, vancomycin). That is the whole rationale for therapeutic drug monitoring: aim for a high peak (to kill) and a low trough (to protect the organs).
Drug names
Indications
- Serious Gram-negative infections (sepsis, complicated UTI, intra-abdominal, pneumonia)
- Synergy with a cell-wall agent for Gram-positive endocarditis
- Inhaled tobramycin for cystic-fibrosis Pseudomonas; topical/ophthalmic use
Mechanism of action
Bind the 30S bacterial ribosomal subunit, causing mRNA misreading and production of defective proteins — bactericidal, concentration-dependent killing with a post-antibiotic effect. Active mainly against aerobic Gram-negative organisms.
Therapeutic effects — what you'll see working
Success is clearing a serious Gram-negative infection, judged clinically and by cultures — while therapeutic drug monitoring keeps the peak high enough to kill and the trough low enough to spare the kidney and ears.
- Bactericidal Gram-negative kill
- Rapidly kills aerobic Gram-negative bacteria; the high peak relative to the organism’s MIC predicts success.
- Synergy with cell-wall agents
- Paired with a beta-lactam or vancomycin, aminoglycosides penetrate better and enhance killing (e.g., in endocarditis).
Adverse effects
The adverse effects are the drug accumulating where it shouldn’t — the kidney, the inner ear, and (rarely) the neuromuscular junction — which is exactly what monitoring is designed to prevent.
Interactions
Contraindications
The labeled contraindication is hypersensitivity (with cross-sensitivity across the class); the other rows are patients in whom accumulation or neuromuscular effects are especially dangerous.
When to hold
Assess before giving — these findings mean hold the dose and act.
Labs & levels
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Aminoglycosides used for?
How do Aminoglycosides work?
What are the serious side effects of Aminoglycosides?
When should a nurse hold Aminoglycosides, and what safety checks apply?
What labs should be monitored with Aminoglycosides?
Conditions treated
Inhaled tobramycin (TOBI) for Pseudomonas. TOBI label: "TOBI is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa." "TOBI is administered twice daily in alternating periods of 28 days. After 28 days of therapy, patients should stop TOBI therapy for the next 28 days." Warnings: bronchospasm; "Tinnitus and hearing loss have been reported in patients receiving TOBI" — "Tinnitus may be a sentinel symptom of ototoxicity"; nephrotoxicity; worsening muscle weakness; "Aminoglycosides can cause fetal harm." "TOBI should not be diluted or mixed with dornase alfa or other medications in the nebulizer."
Gentamicin is a synergy drug, not a routine one. It stays only where synergy is proven: enterococcal IE (with ampicillin or penicillin, 4–6 weeks), the first 2 weeks of staphylococcal prosthetic-valve regimens (with nafcillin or vancomycin plus rifampin), and an optional 2-week short course for streptococcal native-valve IE. The trap: gentamicin is no longer recommended for native-valve MSSA or MRSA — no benefit and real nephrotoxicity. Renal and vestibular toxicity demand therapeutic drug monitoring, especially at home on OPAT.
[Ototoxicity] Hearing hazard. "Aminoglycosides such as gentamicin cause hair cell death resulting in permanent hearing loss and balance dysfunction." Report new tinnitus, hearing change or imbalance. [Ménière’s] Intratympanic gentamicin controls vertigo "but significantly raises the risk of hearing loss."
Gentamicin with clindamycin for endometritis. StatPearls (Endometritis): "Gentamicin 5 mg/kg intravenous every 24 hours (preferred) or 1.5 mg/kg intravenous every 8 hours." Also in the StatPearls SPT regimen (ampicillin, gentamicin, clindamycin).
See also
The original β-lactams — bactericidal cell-wall inhibitors. The defining nursing job is screening for and recognizing allergy, from rash to anaphylaxis.
β-lactam cousins of penicillin, organized by generation — each generation trades some gram-positive reach for broader gram-negative coverage.
Powerful, broad-spectrum DNA-synthesis blockers — but a boxed warning for disabling tendon, nerve, and CNS effects means they’re reserved when alternatives exist.
Suppress viral replication rather than kill viruses outright. The nursing essentials: hydrate with acyclovir, start early (flu within 48 h), and remember most antivirals suppress — they don’t cure.
Broad, generally safe protein-synthesis inhibitors — a penicillin-allergy alternative. Watch QT and CYP3A4.
Broad-spectrum 30S inhibitors. Generally avoided in pregnancy and in children 8 or younger (permanent tooth staining) unless the infection is serious — doxycycline is still first-line for Rocky Mountain spotted fever at any age — and kept apart from dairy/antacids.
Sources
- Aminoglycosides — 30S mechanism, spectrum, nephro-/ototoxicity, monitoring — StatPearls (NCBI)
- Gentamicin — toxicity profile, therapeutic monitoring — StatPearls (NCBI)
- Gentamicin Sulfate Injection — boxed warning (neurotoxicity, neuromuscular blockade, fetal harm), FDA label — FDA / DailyMed
- Creatinine Clearance — serum creatinine reference ranges — StatPearls (NCBI)
- Amikacin sulfate injection — boxed warning incl. neuromuscular blockade (FDA label) — FDA / DailyMed
- Tobramycin for injection — boxed warning (FDA label) — FDA / DailyMed
- Aminoglycoside-induced hearing loss — peak/trough targets (Front Pharmacol 2026) — PMC (CC BY)
- Antimicrobials — Aminoglycosides (Nursing Pharmacology) — Open RN (NCBI Bookshelf)
- Fluids and Electrolytes — BUN reference range (Nursing Fundamentals) — Open RN (NCBI Bookshelf)
- Pharmacokinetics — peak and trough levels (Nursing Pharmacology) — Open RN (NCBI Bookshelf)
- The use of stems in the selection of International Nonproprietary Names (-micin, -mycin, -kacin) — World Health Organization
- Tobrex (tobramycin ophthalmic ointment) — FDA label — FDA / DailyMed
- Pregnancy Medications — aminoglycosides generally avoided; life-threatening maternal sepsis — StatPearls (NCBI)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.